检测或抑制TCF7L2-Exon14剪切异构体的试剂的应用、口腔癌治疗药物
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CENT SOUTH UNIV
- Filing Date
- 2026-03-11
- Publication Date
- 2026-07-17
AI Technical Summary
Oral cancer has a high recurrence and metastasis rate, and early diagnosis is difficult. Current treatments have not been able to effectively improve patients' survival rate and quality of life, and there is a lack of effective molecular markers and precision treatment strategies.
By detecting and inhibiting the TCF7L2-Exon14 splice isoform, PCR detection reagents and shRNA preparations were used for the diagnosis and treatment of oral cancer. The high expression of the TCF7L2-L splice isoform was detected and its function was inhibited, and the oncogene function of the TCF7L2-L splice isoform in oral cancer cells was utilized.
It enables early prediction and molecular subtyping of oral cancer, improving diagnostic accuracy, and provides a new therapeutic target to improve treatment efficacy by inhibiting the TCF7L2-L cleavage isoform to slow cancer cell proliferation and colony formation.
Smart Images
Figure CN121874348B_ABST